Investing

Lexicon Pharmaceuticals : LXRX

LXRX

Stock Data

$1.63

$0.02 (1.24%)

Asset Type

Common Stock

Exchange

NASDAQ

Currency

USD

Country

USA

Sector

HEALTHCARE

Industry

BIOTECHNOLOGY

Lexicon Pharmaceuticals Inc is a biopharmaceutical company based in The Woodlands, Texas, dedicated to developing pharmaceutical products. It focuses on creating orally-delivered small molecule drugs for conditions like heart failure, type 1 diabetes, and neuropathic pain. Its leading drug candidates include Sotagliflozin, in advanced clinical trials for heart failure and diabetes, and LX9211 and LX2761, targeting neuropathic pain and gastrointestinal issues, respectively. Lexicon also collaborates with industry giants like Bristol-Myers Squibb and Genentech to enhance its research and development efforts.

All Lexicon Pharmaceuticals Articles

38 Articles

Joshua Rodriguez | Jul 30, 2024 at 8:49 AM EDT

5 Penny Stocks With 250% Upside in 1 Year According to Wall Street

Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the…

Chris Lange | Aug 12, 2022 at 10:50 AM EDT

A Recovery in the Works? Analysts Upgrade or Downgrade Lennar, RealReal, Six Flags and More

Friday's additional top analyst upgrades and downgrades were on Ciena, Lennar, Lexicon Pharmaceuticals, Mister Car Wash, PagerDuty, RealReal, Six Flags…

Chris Lange | Jan 29, 2021 at 3:34 PM EST

Biogen, 3D Systems, Duke Energy, Ford and More of Friday Afternoon’s Analyst Calls

The Friday afternoon analyst calls were focused on Biogen, 3D Systems, Duke Energy, Ford, and more.

Chris Lange | Jan 14, 2021 at 10:00 AM EST

Is Lexicon Pharma a Stock to Buy After 90% Runup and FDA Nod?

Lexicon Pharma shares jumped on Thursday morning after the company announced that it received regulatory feedback from the FDA regarding…

Chris Lange | Aug 11, 2020 at 9:41 AM EDT

5 Speculative Biotechs With 50% to 300% Implied Upside

24/7 Wall St. has compiled a list of some speculative biotech plays that could see gains of up to 300%…

Chris Lange | Jul 21, 2020 at 10:56 AM EDT

Late-Stage Diabetes Study Sets the Stage for Lexicon Pharma

Lexicon Pharmaceuticals shares surged on Tuesday after the company announced positive topline data for its late-stage studies in type 2…

Chris Lange | Sep 11, 2019 at 1:35 PM EDT

What’s Left After Lexicon’s Terminated Partnership With Sanofi

After Lexicon Pharmaceuticals announced the termination of its alliance with Sanofi, its shares rallied on Wednesday.

Chris Lange | Jul 29, 2019 at 11:20 AM EDT

Is This Lexicon Pharmaceuticals Panic Overblown?

Lexicon Pharma shares were absolutely crushed on Monday after it was announced that Sanofi would be ending its partnership with…

Chris Lange | Mar 1, 2019 at 11:30 AM EST

What Lexicon Pharma Could Mean for the Future of Diabetes

Lexicon shares jumped on Friday after the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive…

Paul Ausick | Jan 25, 2019 at 12:30 PM EST

Vodafone, Lexicon Pharma Slip Into Friday’s 52-Week Low Club

Vodafone, Lexicon Pharmaceuticals, Amneal Pharmaceuticals, and Maiden Holding had all posted new 52-week lows by noon Friday.

Paul Ausick | Jan 18, 2019 at 12:15 PM EST

Immunomedics, Nautilus Sink Into Friday’s 52-Week Low Club

Immunomedics, Signet Jewelry, Nautilus, and Lexicon Pharmaceuticals had all posted new 52-week lows by noon Friday.

Chris Lange | Jan 18, 2019 at 11:06 AM EST

FDA Diabetes Treatment Vote to Determine the Fate of Lexicon Therapeutics?

Lexicon shares fell on Friday after the FDA voted to approve the firm’s type 1 diabetes treatment. Although the result…

Chris Lange | Jun 24, 2018 at 10:15 AM EDT

Biopharma Companies to Watch This Week

Here, 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week…

Chris Lange | Jun 9, 2018 at 9:25 AM EDT

Biopharma Companies to Watch This Week and for the Rest of June

Here 24/7 Wall St. has included a calendar of a few of companies to watch for in the coming week…

Jon C. Ogg | Apr 16, 2018 at 9:00 AM EDT

Top Analyst Upgrades and Downgrades: AEP, American Water, BHP Billiton, Boeing, Costco, Crocs, Dollar General, McDonald’s, Ulta Beauty and More

The top analyst upgrades, downgrades and other research calls from Monday include American Electric Power, American Water Works, BHP Billiton,…